The company's shares closed last Monday at $6.81, close to its 52-week low of $3.50. According to TipRanks.com, Mamtani is a 4-star analyst with an average return of 10.8% and a 41.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals. Currently, the analyst consensus on Vaxart is a Moderate Buy with an average price target of $13.50. See today’s analyst top recommended stocks >> Based on Vaxart's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $112K and GAAP net loss of $16.12 million. In comparison, last year the company earned revenue of $523K and had a GAAP net loss of $8.98 million. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Biota Holdings Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. Read More on VXRT: Maxim Group Thinks MTBC’s Stock is Going to Recover SilverBow Resources to Acquire Oil & Gas Assets in Eagle Ford AT&T Partners with Ericsson to Expand 5G Network Coverage Tenet’s USPI Agrees to Acquire Minority Stake in 9 ASCs from Compass Kronos Bio (KRON) Receives a Buy from H.C. Wainwright